Questions · Sugammadex versus Neostigmine for Reversal
8 questions, 0 approved. Approve them one at a time — a quiz shows nothing you have not.
Recall — derived from a kept point
What two aspects of neuromuscular blockade management does the 2023 ASA practice guideline address, and what is its explicitly stated aim?
Answer: It directs both how neuromuscular blockade is monitored and how it is antagonised, with the explicit aim of reducing residual blockade after general anaesthesia.
Monitoring and reversal are handled in one guideline for a reason — the shared goal is keeping residual blockade out of recovery.
Source claim: The 2023 ASA practice guideline directs both how neuromuscular blockade is monitored and how it is antagonised, with the explicit aim of reducing residual blockade after general anaesthesia.
2023 American Society of Anesthesiologists Practice Guidelines for Monitoring and Antagonism of Neuromuscular Blockade: A Report by the American Society of Anesthesiologists Task Force on Neuromuscular Blockade, Anesthesiology 2023
recall · CA-1 · phrased by llm
In the randomised trial of patients over 70 having surgery of three hours or more, what happened to the rate of residual paralysis in recovery with sugammadex compared with neostigmine, and what happened to postoperative pulmonary complications?
Answer: Residual paralysis in recovery fell from 49% with neostigmine to 10% with sugammadex, but there was no significant difference in postoperative pulmonary complications between the two groups.
Sugammadex clearly fixed the twitch in this trial, and that still did not produce a significant difference in pulmonary complications.
Source claim: In patients over 70 having surgery of three hours or more, sugammadex cut residual paralysis in recovery from 49% to 10% versus neostigmine, without a significant difference in postoperative pulmonary complications.
Randomised Controlled Trial of Sugammadex or Neostigmine for Reversal of Neuromuscular Block on the Incidence of Pulmonary Complications in Older Adults Undergoing Prolonged Surgery, British journal of anaesthesia 2020
recall · CA-2 · phrased by llm
A resident cites the STRONGER analysis of 45,712 matched inpatients as proof that sugammadex prevents postoperative pneumonia. State what that analysis actually reported and what its design does not let you claim.
Answer: It reported that sugammadex was associated with a 30% lower risk of major pulmonary complications, a 47% lower risk of pneumonia and a 55% lower risk of respiratory failure than neostigmine. Those are associations from a matched cohort, not results of a randomised comparison, so they do not establish that sugammadex prevents these complications.
Keep the word 'associated with' — a matched cohort of 45,712 patients is still an association, however large the numbers look.
Source claim: Across 45,712 matched inpatients, sugammadex was associated with a 30% lower risk of major pulmonary complications, a 47% lower risk of pneumonia and a 55% lower risk of respiratory failure than neostigmine.
Sugammadex Versus Neostigmine for Reversal of Neuromuscular Blockade and Postoperative Pulmonary Complications (STRONGER): A Multicenter Matched Cohort Analysis, Anesthesiology 2020
recall · CA-3 · phrased by llm
A patient with myasthenia gravis has received rocuronium. What does the reported case experience show can happen after a large dose of sugammadex, and what practical step does it argue for?
Answer: Sugammadex can fail in myasthenia gravis: in a reported case, 800 mg left the train-of-four ratio stuck at 60% until neostigmine was given. The practical step is to monitor the block rather than assuming that a dose of sugammadex has reversed it.
One reported failure is enough to change your habit here: in myasthenia gravis, confirm reversal on the monitor instead of assuming the dose worked.
Source claim: Sugammadex can fail in myasthenia gravis — 800 mg left the train-of-four ratio stuck at 60% until neostigmine was given — so monitor the block rather than assuming reversal.
Failure of Reversion of Neuromuscular Block With Sugammadex in Patient With Myasthenia Gravis: Case Report and Brief Review of Literature, BMC anesthesiology 2019
recall · CA-2 · phrased by llm
The point with one number taken out. No model wrote any of this: the stem is the sentence you reviewed, minus a digit, and the paper it came from is named beneath it.
Open prompts
Walk me through your setup for this before we start.
open · CA-1 · phrased by derived
What are you watching on the monitor that would tell you this is going wrong?
open · CA-1 · phrased by derived
What is your first move if it does?
open · CA-1 · phrased by derived
What would you want ready in the room before induction?
open · CA-1 · phrased by derived
Questions only — nothing here asserts anything, which is why a model is allowed to phrase them. Where no model was reachable these are the level defaults.